Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug;38(8):1307-1326.
doi: 10.1007/s11095-021-03080-2. Epub 2021 Jul 23.

Carboxylic Acid Counterions in FDA-Approved Pharmaceutical Salts

Sonali S Bharate  1
Affiliations
Review

Carboxylic Acid Counterions in FDA-Approved Pharmaceutical Salts

Sonali S Bharate. Pharm Res. 2021 Aug.

Abstract

Salification is one of the powerful and widely employed approaches to improve the biopharmaceutical properties of drugs. The FDA's eighty-year trajectory of new drug approvals depicts around one-third of the drugs clinically used as their pharmaceutical salts. Among various cationic and anionic counterions used in FDA-approved pharmaceutical salts, the carboxylic acids have significantly contributed. A total of 94 pharmaceutical salts discovered during 1943-2020 comprises carboxylic acids as counterions with a major contribution of acetate, maleate, tartrate, fumarate, and succinate. Hydrocodone tartrate is the first FDA-approved carboxylate salt approved in 1943. Overall, the analysis shows that fifteen carboxylic acid counterions are present in FDA-approved pharmaceutical salts with a major share of acetate (18 drugs). This review provides an account of FDA-approved carboxylate salts from 1939 to 2020. The decade-wise analysis indicates that 1991-2000 contributed a maximum number of carboxylate salts (24) and least (3) in 1939-1950. The technical advantage of carboxylate salts over free-base or other counterions is also discussed. Graphical Abstract.

Keywords: US FDA; biopharmaceutical properties; carboxylic acid counterions; enhanced bioavailability; pharmaceutical salts; weakly basic drugs.

PubMed Disclaimer

References

    1. Paulekuhn GS, Dressman JB, Saal C. Trends in active pharmaceutical ingredient salt selection based on analysis of the Orange book database. J Med Chem. 2007;50(26):6665–72. - PubMed - DOI
    1. Saal C, Becker A. Pharmaceutical salts: a summary on doses of salt formers from the Orange book. Eur J Pharm Sci. 2013;49(4):614–23. - PubMed - DOI
    1. Serajuddin AT. Salt formation to improve drug solubility. Adv Drug Deliv Rev. 2007;59(7):603–16. - PubMed - DOI
    1. Morris KR, Fakes MG, Thakur AB, Newman AW, Singh AK, Venit JJ, et al. An integrated approach to the selection of optimal salt form for a new drug candidate. Int J Pharm. 1994;105:209–17. - DOI
    1. Khorana AB. A controlled double blind comparative study of single dose administration of imipramine pamoate and divided dose of imipramine hydrochloride in depressive illness. Indian J Physiol Pharmacol. 1981;25(4):331–8. - PubMed

MeSH terms

LinkOut - more resources